Brett King

11.3k total citations · 6 hit papers
175 papers, 6.5k citations indexed

About

Brett King is a scholar working on Urology, Dermatology and Pathology and Forensic Medicine. According to data from OpenAlex, Brett King has authored 175 papers receiving a total of 6.5k indexed citations (citations by other indexed papers that have themselves been cited), including 78 papers in Urology, 56 papers in Dermatology and 49 papers in Pathology and Forensic Medicine. Recurrent topics in Brett King's work include Hair Growth and Disorders (78 papers), Autoimmune Bullous Skin Diseases (43 papers) and Dermatology and Skin Diseases (21 papers). Brett King is often cited by papers focused on Hair Growth and Disorders (78 papers), Autoimmune Bullous Skin Diseases (43 papers) and Dermatology and Skin Diseases (21 papers). Brett King collaborates with scholars based in United States, Australia and Japan. Brett King's co-authors include Brittany G. Craiglow, William Damsky, Lucy Liu, Shanta R. Dube, Rutul Patel, Karena H. Nguyen, Steven G. Boxer, Gabbi Promoff, Sameer Alam and René A. Arrazola and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Brett King

165 papers receiving 6.3k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trends in Awareness and Use of Electronic Cigarettes Among US Adults, 2010-2013

2014 441 citations Brett King et al. profile →
JAK inhibitors in dermatology: The promise of a new drug class

2017 357 citations William Damsky, Brett King Journal of the American Academy of Dermatology profile →
Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients

2016 241 citations Brett King et al. Journal of the American Academy of Dermatology profile →
A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results

2021 138 citations Brett King, Emma Guttman‐Yassky et al. Journal of the American Academy of Dermatology profile →
Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial

2023 134 citations Brett King, Natasha Atanaskova Mesinkovska et al. profile →
Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2)

2023 65 citations Ohsang Kwon, Maryanne M. Senna et al. American Journal of Clinical Dermatology profile →

Peers

Countries citing papers authored by Brett King

Since Specialization

Citations

This map shows the geographic impact of Brett King's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brett King with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brett King more than expected).

Fields of papers citing papers by Brett King

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brett King. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brett King. The network helps show where Brett King may publish in the future.

Co-authorship network of co-authors of Brett King

This figure shows the co-authorship network connecting the top 25 collaborators of Brett King. A scholar is included among the top collaborators of Brett King based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brett King. Brett King is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and safety of etrasimod in alopecia areata: A multicentre, randomized, double‐blind, placebo‐controlled, Phase 2 study 2025 ·Journal of the European Academy of Dermatology and Venereology ·Brett King, Natasha Atanaskova Mesinkovska, Maryanne M. Senna, Xin Luo, (unknown), Andrew Selfridge	1
2	Visualizing Severity of Alopecia Tool (SALT) scores in the clinical setting using patient images from a clinical trial 2024 ·SHILAP Revista de lepidopterología ·Natasha Atanaskova Mesinkovska, Brett King, Sergio Vañó‐Galván, Yutaka Shimomura, Jakub Jedynak, Jill Shwed McCollam, Evangeline Pierce, (unknown), Rodney Sinclair	3
3	Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program 2024 ·American Journal of Clinical Dermatology ·Brett King, Jennifer Soung, Christos Tziotzios, Lidia Rudnicka, P. Joly, Melinda Gooderham, Rodney Sinclair, Natasha Atanaskova Mesinkovska, C. Paul, (unknown), (unknown), Helen Tran, Robert Wołk, Samuel H. Zwillich, (unknown)	27
4	Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2 2024 ·Journal of the European Academy of Dermatology and Venereology ·Maryanne M. Senna, Arash Mostaghimi, Manabu Ohyama, Rodney Sinclair, Yves Dutronc, (unknown), Guanglei Yu, Carla Fabiana Chiasserini, Najwa Somani, Katrin Holzwarth, Brett King	21
5	Inhibition of T-cell activity in alopecia areata: recent developments and new directions 2023 ·Frontiers in Immunology ·Thierry Passeron, Brett King, Julien Sénéschal, Martin Steinhoff, Ali Jabbari, Manabu Ohyama, Desmond J. Tobin, Simran Randhawa, Aaron Winkler, Jean‐Baptiste Telliez, David E. Martin, (unknown)	40
6	41701 Efficacy of the Oral JAK1/JAK2 Inhibitor CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata: Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 Phase 3 Trial 2023 ·Journal of the American Academy of Dermatology ·Maryanne M. Senna, Brett King, Natasha Atanaskova Mesinkovska, Arash Mostaghimi, (unknown), James V. Cassella	1
7	43117 Integrated safety analysis of ritlecitinib in adolescent patients with alopecia areata from the randomized, placebo-controlled ALLEGRO phase 2b/3 and ongoing open-label phase 3 ALLEGRO-LT studies 2023 ·Journal of the American Academy of Dermatology ·Jennifer Soung, Brett King, Christos Tziotzios, Lidia Rudnicka, P. Joly, Melinda Gooderham, Rodney Sinclair, Fan Zhang, Helen Tran, Robert Wołk	1
8	Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2) breakdown → 2023 ·American Journal of Clinical Dermatology ·Ohsang Kwon, Maryanne M. Senna, Rodney Sinclair, Taisuke Ito, Yves Dutronc, Chen‐Yen Lin, Guanglei Yu, (unknown), Jill Shwed McCollam, Wen-Shuo Wu, Brett King	65
9	Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials 2022 ·British Journal of Dermatology ·Brett King, Arash Mostaghimi, Yutaka Shimomura, Abraham Zlotogorski, Gwang Seong Choi, Ulrike Blume‐Peytavi, Thierry Passeron, Katrin Holzwarth, Yves Dutronc, Jill Shwed McCollam, Fan Emily Yang, Sarah Stanley, Wen-Shuo Wu, Rodney Sinclair	37
10	Using qualitative methods to establish the clinically meaningful threshold for treatment success in alopecia areata 2022 ·Quality of Life Research ·Kathleen W. Wyrwich, Helen Kitchen, S.L. Knight, Natalie V. J. Aldhouse, Jake Macey, Natasha Atanaskova Mesinkovska, Justin Ko, Brett King	4
11	Safety and Efficacy of Ritlecitinib and Brepocitinib in Alopecia Areata: Results from the Crossover Open-Label Extension of the ALLEGRO Phase 2a Trial 2022 ·SHILAP Revista de lepidopterología ·Brett King, Emma Guttman‐Yassky, Elena Peeva, Anindita Banerjee, Linda Zhu, (unknown), Lori Ann Cox, Michael S. Vincent, Rodney Sinclair	15
12	Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis 2022 ·Nature Communications ·William Damsky, Alice Wang, Daniel Kim, Bryan D. Young, (unknown), Michael J. Murphy, (unknown), (unknown), Rüveyda Ayasun, Changwan Ryu, Meaghan K. McGeary, Ian D. Odell, (unknown), Darko Pucar, Robert Homer, Mridu Gulati, Edward J. Miller, Marcus Bosenberg, Richard A. Flavell, Brett King	62
13	Cytokine RNA In Situ Hybridization Permits Individualized Molecular Phenotyping in Biopsies of Psoriasis and Atopic Dermatitis 2021 ·SHILAP Revista de lepidopterología ·Alice Wang, Alexander L. Fogel, Michael J. Murphy, Gauri Panse, Meaghan K. McGeary, Jennifer M. McNiff, Marcus Bosenberg, Matthew D. Vesely, Jeffrey M. Cohen, Christine J. Ko, Brett King, William Damsky	26
14	Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers 2021 ·Journal of Allergy and Clinical Immunology ·Emma Guttman‐Yassky, Ana B. Pavel, Aisleen Diaz, Ning Zhang, Ester Del Duca, Yeriel Estrada, Brett King, Anindita Banerjee, Christopher Banfield, Lori Ann Cox, Martin E. Dowty, Karen Page, Michael S. Vincent, Weidong Zhang, Linda Zhu, Elena Peeva	74
15	A qualitative interview study to explore adolescents’ experience of alopecia areata and the content validity of sign/symptom patient‐reported outcome measures* 2021 ·British Journal of Dermatology ·Jake Macey, Helen Kitchen, Natalie V. J. Aldhouse, Emily Edson‐Heredia, Russel Burge, (unknown), Brett King, Natasha Atanaskova Mesinkovska	6
16	The Alopecia Areata Investigator Global Assessment scale: a measure for evaluating clinically meaningful success in clinical trials 2020 ·British Journal of Dermatology ·Kathleen W. Wyrwich, Helen Kitchen, S.L. Knight, Natalie V. J. Aldhouse, Jake Macey, Fabio P. Nunes, Yves Dutronc, Natasha Atanaskova Mesinkovska, Justin Ko, Brett King	67
17	Development of the Scalp Hair Assessment PRO™ measure for alopecia areata 2020 ·British Journal of Dermatology ·Kathleen W. Wyrwich, Helen Kitchen, S.L. Knight, Natalie V. J. Aldhouse, Jake Macey, Fabio P. Nunes, Yves Dutronc, Natasha Atanaskova Mesinkovska, Justin Ko, Brett King	27
18	“‘You lose your hair, what’s the big deal?’ I was so embarrassed, I was so self-conscious, I was so depressed:” a qualitative interview study to understand the psychosocial burden of alopecia areata 2020 ·Journal of Patient-Reported Outcomes ·Natalie V. J. Aldhouse, Helen Kitchen, S.L. Knight, Jake Macey, Fabio P. Nunes, Yves Dutronc, Natasha Atanaskova Mesinkovska, Justin Ko, Brett King, Kathleen W. Wyrwich	57
19	Development of Clinician-Reported Outcome (ClinRO) and Patient-Reported Outcome (PRO) Measures for Eyebrow, Eyelash and Nail Assessment in Alopecia Areata 2020 ·American Journal of Clinical Dermatology ·Kathleen W. Wyrwich, Helen Kitchen, S.L. Knight, Natalie V. J. Aldhouse, Jake Macey, Fabio P. Nunes, Yves Dutronc, Natasha Atanaskova Mesinkovska, Justin Ko, Brett King	41
20	Economies of Scale and the Provision of Public Goods by Municipalities 2004 ·Journal of economics and economic education research ·(unknown), Brett King, (unknown), (unknown)	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact